Market Cap : 75.03 B | Enterprise Value : 66.52 B | PE Ratio : 23.66 | PB Ratio : 6.28 |
---|
NAS:VRTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:VRTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Vertex Pharmaceuticals's enterprise value is $66,521 Mil. Vertex Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Jun. 2022 was $8,350 Mil. Therefore, Vertex Pharmaceuticals's EV-to-Revenue for today is 7.97.
The historical rank and industry rank for Vertex Pharmaceuticals's EV-to-Revenue or its related term are showing as below:
During the past 13 years, the highest EV-to-Revenue of Vertex Pharmaceuticals was 52.73. The lowest was 4.24. And the median was 13.15.
VRTX's EV-to-Revenue is ranked better thanThe reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
As of today (2022-08-12), Vertex Pharmaceuticals's stock price is $293.25. Vertex Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2022 was $32.33. Therefore, Vertex Pharmaceuticals's PS Ratio for today is 9.07.
The historical data trend for Vertex Pharmaceuticals's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vertex Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Vertex Pharmaceuticals's EV-to-Revenue falls into.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
Vertex Pharmaceuticals's EV-to-Revenue for today is calculated as:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 66521.102 | / | 8350.425 | |
= | 7.97 |
Vertex Pharmaceuticals's current Enterprise Value is $66,521 Mil.
Vertex Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $8,350 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
Vertex Pharmaceuticals's PS Ratiofor today is calculated as:
PS Ratio | = | Share Price (Today) | / | Revenue per Share (TTM) |
= | 293.25 | / | 32.327 | |
= | 9.07 |
Vertex Pharmaceuticals's share price for today is $293.25.
Vertex Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $32.33.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Vertex Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Upadhyay Suketu | director | 345 E. MAIN STREET WARSAW IN 46580 |
Garber Alan M | director | 3355 MILTON COURT MOUNTAIN VIEW CA 94040 |
Kearney Terrence C | director | IN CARE OF HOSPIRA, INC. 275 NORTH FIELD DRIVE LAKE FOREST IL 60045 |
Carney Lloyd | director | C/O MICROMUSE INC 139 TOWNSEND ST SAN FRANCISCO CA 94107 |
Mckenzie Diana | director | METLIFE 200 PARK AVENUE NEW YORK NY 10166 |
Bhatia Sangeeta N. | director | C/O VERTEX PHARMACEUTICALS, INC. 50 NORTHERN AVENUE BOSTON MA 02210 |
Lee Yuchun | director | 170 TRACER LA. WALTHAM MA 02451 |
Ambrose Kristen | officer: SVP & Chief Accounting Officer | C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 |
Mcglynn Margaret G | director | C/O MERCK & CO INC ONE MERCK DRIVE PO BOX 100 WHITEHOUSE STATION NJ 08889-0100 |
Liu Joy | officer: SVP, General Counsel | C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 |
Tatsis Ourania | officer: EVP, Chief Reg. & Quality Off. | C/O VERTEX PHARMACEUTICALS, INC. 50 NORTHERN AVENUE BOSTON MA 02210 |
Bozic Carmen | officer: EVP and CMO | C/O VERTEX PHARMACEUTICALS, INC. 50 NORTHERN AVENUE BOSTON MA 02210 |
Wagner Charles F Jr | officer: EVP & Chief Financial Officer | C/O MILLIPORE CORP BILLERICA MA 01820 |
Arbuckle Stuart A | officer: EVP, COO | VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY ST. CAMBRIDGE MA 02139 |
Kewalramani Reshma | director, officer: CEO & President | C/O VERTEX PHARMACEUTICALS, INC. 50 NORTHERN AVENUE BOSTON MA 02210 |
Other Sources
By Zacks 2022-03-29
By Zacks 2022-03-29
By Zacks 2022-03-25
By Zacks 2022-04-01
By Zacks 2022-04-05
By Zacks 2022-04-04
By Zacks 2022-03-24
By Zacks 2022-03-29
By Zacks 2022-03-29
By Zacks 2022-03-25
By Zacks 2022-03-28
By Zacks 2022-03-28
By Zacks 2022-03-25
By Fool 2022-04-01
By Zacks 2022-03-30